Stay Informed

Get email alerts when new recalls match your interests.

Recall data is updated hourly from official government sources. Very recent recalls may not yet appear. About our data sources

About

We make U.S. recall data searchable and accessible for consumers and businesses.

Site

FAQ
Browse by State
Statistics
Recall Classifications
About
Enterprise API

Legal

Privacy Policy
Terms of Service
Report Incorrect Info

Official Sources

FDA Recalls ↗
USDA FSIS ↗
CPSC Recalls ↗
NHTSA Recalls ↗

RSS Feed

Home
/
Brands
/
Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc. Recalls

All product recalls associated with Boehringer Ingelheim Pharmaceuticals, Inc..

Get alerts for this brand

Recall Summary

Total Recalls

Past Year

Class I (Serious)

Most Recent

Mar 2023

Data from FDA, USDA, CPSC, and NHTSA public records. Recall counts vary by company size, industry, and reporting practices. Always check official sources for current information.

Showing 1–12 of 12 recalls

Jardiance 25mg Tablets (Boehringer) – Label Mix-up (2023)

Labeling: Label Mix-up

Class IIModerate

FDAMar 9, 2023Nationwide• Boehringer Ingelheim Pharmaceuticals, Inc.

Micardis Tablets (Boehringer) – Subpotent Drug (2021)

Subpotent Drug

Class IIModerate

FDAMay 4, 2021AR, CO, CT +8 more• Boehringer Ingelheim Pharmaceuticals, Inc.

Catapres 0.3mg (Boehringer Ingelheim) – Dissolution Peak (2020)

An extraneous peak was observed for dissolution testing.

Class IIModerate

FDA

Oct 5, 2020

Nationwide

• Boehringer Ingelheim Pharmaceuticals, Inc.

Catapres (Boehringer Ingelheim) – Dissolution Peak (2020)

An extraneous peak was observed for dissolution testing.

Class IIModerate

FDAOct 5, 2020Nationwide• Boehringer Ingelheim Pharmaceuticals, Inc.

Catapres (Boehringer Ingelheim) - Dissolution Testing Issue (2020)

An extraneous peak was observed for dissolution testing.

Class IIModerate

FDAOct 5, 2020Nationwide• Boehringer Ingelheim Pharmaceuticals, Inc.

Mirapex Tablets (Boehringer) – Weight Specification Failure (2019)

Failed Tablet/Capsule Specifications: identification of low weight tablets during routine stability testing.

Class IIILow

FDAMar 7, 2019Nationwide• Boehringer Ingelheim Pharmaceuticals, Inc.

Catapres .2 (Boehringer) – Dissolution Specification Failure (2018)

Failed Dissolution Specifications: OOS resultsduring routine stability testing

Class IIModerate

FDAOct 22, 2018Nationwide• Boehringer Ingelheim Pharmaceuticals, Inc.

Synjardy Tablets (Boehringer) – product contamination (2018)

Cross Contamination With Other Products:

Class IIModerate

FDASep 4, 2018Nationwide• Boehringer Ingelheim Pharmaceuticals, Inc.

SPIRIVA HandiHaler (Boehringer) – Stability Specification Failure (2017)

Failed Stability Specifications

Class IIModerate

FDADec 14, 2017Nationwide• Boehringer Ingelheim Pharmaceuticals, Inc.

Mobic Tablets (Boehringer) – Incorrect Package Insert (2017)

Labeling: Incorrect or missing package insert. One lot of Mobic Tablets is packaged with an incorrect insert.

Class IIILow

FDASep 22, 2017CO, OH• Boehringer Ingelheim Pharmaceuticals, Inc.

Dipyridamole Tablets (Boehringer) – Foreign Tablets (2016)

Presence of foreign tablets/capsules: 50 mg Persantine tablets were found in a 75 mg Persantine 100-count bottle and 50 mg Persantine tablet was found in a 100 count bottle of 75 mg Dipyridamole.

Class IIModerate

FDAOct 6, 2016Nationwide• Boehringer Ingelheim Pharmaceuticals, Inc.

Persantine (Boehringer) – Foreign Tablets (2016)

Presence of foreign tablets/capsules: 50 mg Persantine tablets were found in a 75 mg Persantine 100-count bottle and 50 mg Persantine tablet was found in a 100 count bottle of 75 mg Dipyridamole.

Class IIModerate

FDAOct 6, 2016Nationwide• Boehringer Ingelheim Pharmaceuticals, Inc.